<DOC>
	<DOCNO>NCT02373046</DOCNO>
	<brief_summary>This randomize , single-center , open-label , 2-sequence , 2-period , single-dose , crossover study assess bioequivalence total 24-hour urinary glucose excretion ( UGE ) 400 mg LX4211 administer single 400-mg tablet compare 2 × 200-mg tablet healthy subject fast condition .</brief_summary>
	<brief_title>Bioequivalence Study Between 400 mg LX4211 Tablets 2 X 200 mg LX4211 Tablets</brief_title>
	<detailed_description />
	<criteria>Adult subject ≥18 ≤55 year age Willing able provide write informed consent Presence clinically significant physical , laboratory , ECG finding , opinion Investigator and/or Sponsor , may interfere aspect study conduct interpretation result Existence surgical medical condition might interfere absorption , distribution , metabolism , excretion LX4211 History renal disease , significantly abnormal kidney function test Screening History hepatic disease , significantly abnormal liver function test Screening History clinically relevant psychiatric , renal , hepatic , pancreatic , endocrine , cardiovascular , neurological , hematological , GI abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>